Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q2 Losses Hold Steady

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.

The company's loss of the three-month period ended June 30 was $2 million, the same as the year before. Research and development spending held steady at $1.2 million, while general and administrative costs edged up $100,000 to $1 million.

At the end of the quarter, RXi had cash and cash equivalents of roughly $11.9 million.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.